IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease. This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel multitargeting hybrid molecule, on L-DOPA-induced dyskinesias...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a0e8c09c50324d6781ab9cf6c5f0a633 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a0e8c09c50324d6781ab9cf6c5f0a633 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a0e8c09c50324d6781ab9cf6c5f0a6332021-11-18T08:02:48ZIRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.1932-620310.1371/journal.pone.0052680https://doaj.org/article/a0e8c09c50324d6781ab9cf6c5f0a6332013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23300984/?tool=EBIhttps://doaj.org/toc/1932-6203The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease. This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel multitargeting hybrid molecule, on L-DOPA-induced dyskinesias (LIDs) and hypolocomotor activity in a non-human primate model of PD. IRC-082451 displays multiple properties: it inhibits neuronal excitotoxicity (sodium channel blocker), oxidative stress (antioxidant) and neuroinflammation (cyclooxygenase inhibitor) and is endowed with mitochondrial protective properties. Animals received daily MPTP injections until stably parkinsonian. A daily treatment with increasing doses of L-DOPA was administered to parkinsonian primates until the appearance of dyskinesias. Then, different treatment regimens and doses of IRC-082451 were tested and compared to the benchmark molecule amantadine. Primates were regularly filmed and videos were analyzed with specialized software. A novel approach combining the analysis of dyskinesias and locomotor activity was used to determine efficacy. This analysis yielded the quantification of the total distance travelled and the incidence of dyskinesias in 7 different body parts. A dose-dependent efficacy of IRC-082451 against dyskinesias was observed. The 5 mg/kg dose was best at attenuating the severity of fully established LIDs. Its effect was significantly different from that of amantadine since it increased spontaneous locomotor activity while reducing LIDs. This dose was effective both acutely and in a 5-day sub-chronic treatment. Moreover, positron emission tomography scans using radiolabelled dopamine demonstrated that there was no direct interference between treatment with IRC-082451 and dopamine metabolism in the brain. Finally, post-mortem analysis indicated that this reduction in dyskinesias was associated with changes in cFOS, FosB and ARC mRNA expression levels in the putamen. The data demonstrates the antidyskinetic efficacy of IRC-082451 in a primate model of PD with motor complications and opens the way to the clinical application of this treatment for the management of LIDs.Romina Aron BadinBrigitte SpinnewynMarie-Claude GaillardCaroline JanCarole MalgornNadja Van CampFrédéric DolléMartine GuillermierSabrina BouletAnne BertrandMarc SavastaMichel AuguetEmmanuel BrouilletPierre-Etienne ChabrierPhilippe HantrayePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 1, p e52680 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Romina Aron Badin Brigitte Spinnewyn Marie-Claude Gaillard Caroline Jan Carole Malgorn Nadja Van Camp Frédéric Dollé Martine Guillermier Sabrina Boulet Anne Bertrand Marc Savasta Michel Auguet Emmanuel Brouillet Pierre-Etienne Chabrier Philippe Hantraye IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. |
| description |
The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease. This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel multitargeting hybrid molecule, on L-DOPA-induced dyskinesias (LIDs) and hypolocomotor activity in a non-human primate model of PD. IRC-082451 displays multiple properties: it inhibits neuronal excitotoxicity (sodium channel blocker), oxidative stress (antioxidant) and neuroinflammation (cyclooxygenase inhibitor) and is endowed with mitochondrial protective properties. Animals received daily MPTP injections until stably parkinsonian. A daily treatment with increasing doses of L-DOPA was administered to parkinsonian primates until the appearance of dyskinesias. Then, different treatment regimens and doses of IRC-082451 were tested and compared to the benchmark molecule amantadine. Primates were regularly filmed and videos were analyzed with specialized software. A novel approach combining the analysis of dyskinesias and locomotor activity was used to determine efficacy. This analysis yielded the quantification of the total distance travelled and the incidence of dyskinesias in 7 different body parts. A dose-dependent efficacy of IRC-082451 against dyskinesias was observed. The 5 mg/kg dose was best at attenuating the severity of fully established LIDs. Its effect was significantly different from that of amantadine since it increased spontaneous locomotor activity while reducing LIDs. This dose was effective both acutely and in a 5-day sub-chronic treatment. Moreover, positron emission tomography scans using radiolabelled dopamine demonstrated that there was no direct interference between treatment with IRC-082451 and dopamine metabolism in the brain. Finally, post-mortem analysis indicated that this reduction in dyskinesias was associated with changes in cFOS, FosB and ARC mRNA expression levels in the putamen. The data demonstrates the antidyskinetic efficacy of IRC-082451 in a primate model of PD with motor complications and opens the way to the clinical application of this treatment for the management of LIDs. |
| format |
article |
| author |
Romina Aron Badin Brigitte Spinnewyn Marie-Claude Gaillard Caroline Jan Carole Malgorn Nadja Van Camp Frédéric Dollé Martine Guillermier Sabrina Boulet Anne Bertrand Marc Savasta Michel Auguet Emmanuel Brouillet Pierre-Etienne Chabrier Philippe Hantraye |
| author_facet |
Romina Aron Badin Brigitte Spinnewyn Marie-Claude Gaillard Caroline Jan Carole Malgorn Nadja Van Camp Frédéric Dollé Martine Guillermier Sabrina Boulet Anne Bertrand Marc Savasta Michel Auguet Emmanuel Brouillet Pierre-Etienne Chabrier Philippe Hantraye |
| author_sort |
Romina Aron Badin |
| title |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. |
| title_short |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. |
| title_full |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. |
| title_fullStr |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. |
| title_full_unstemmed |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. |
| title_sort |
irc-082451, a novel multitargeting molecule, reduces l-dopa-induced dyskinesias in mptp parkinsonian primates. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/a0e8c09c50324d6781ab9cf6c5f0a633 |
| work_keys_str_mv |
AT rominaaronbadin irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT brigittespinnewyn irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT marieclaudegaillard irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT carolinejan irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT carolemalgorn irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT nadjavancamp irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT fredericdolle irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT martineguillermier irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT sabrinaboulet irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT annebertrand irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT marcsavasta irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT michelauguet irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT emmanuelbrouillet irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT pierreetiennechabrier irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates AT philippehantraye irc082451anovelmultitargetingmoleculereducesldopainduceddyskinesiasinmptpparkinsonianprimates |
| _version_ |
1718422620263677952 |